Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT04414969
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
UNKNOWNPHASE2INTERVENTIONAL
Trial Details
Start: 2020-06-26Est. Completion: 2022-07-01
Enrollment target: 35 participants Locations- Hunan Cancer Hospital, Changsha, Hunan, China
Other microbiome trials you might be interested in
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaRecurrent MelanomaUnresectable Melanoma
This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trameti…
Birmingham, United StatesEst. completion Sep 30, 2023
Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma
Background:
Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is t…
Bethesda, United StatesCompleted Dec 31, 2031
Lung Cancer
The purpose of this study is to examine the feasibility and effects of 12-week exercise training at different intensitie…
Boston, United StatesEst. completion Dec 31, 2027